Recently, using the model of cervical cancer, Smola demonstrated that PolyI:C driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in neoplastic cells, suggesting RIPK3 as a novel predictive marker for personalization of cancer immunotherapy [113]. The gene discussed is RIPK3; the disease is cervical cancer.